These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 23462434)
1. Pulmonary complications of biological therapies in children and adults with rheumatic diseases. Nisar MK; Ostör AJ Paediatr Respir Rev; 2013 Dec; 14(4):236-41. PubMed ID: 23462434 [TBL] [Abstract][Full Text] [Related]
2. The therapeutic journey of biologic agents: There will be an end? Atzeni F; Sarzi-Puttini P Pharmacol Res; 2019 Sep; 147():104340. PubMed ID: 31276775 [TBL] [Abstract][Full Text] [Related]
3. Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases. Brites L; Madeira N; Rodrigues J; Marona J; Martins N; Águeda A; Freitas R; Neto A; Capela S; Sequeira G; Ganhão S; Duarte C; Santiago M; Santos MJ Acta Reumatol Port; 2019; 44(4):266-272. PubMed ID: 32008032 [TBL] [Abstract][Full Text] [Related]
4. Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. King LK; Lee A; Anandacoomarasamy A Intern Med J; 2012 May; 42(5):523-31. PubMed ID: 21790927 [TBL] [Abstract][Full Text] [Related]
9. Biological therapy and neurological manifestations. What do we know? Tejera-Segura B; Ferraz-Amaro I Reumatol Clin; 2017; 13(2):102-106. PubMed ID: 27373584 [TBL] [Abstract][Full Text] [Related]
10. [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients]. Gómez Reino J; Loza E; Andreu JL; Balsa A; Batlle E; Cañete JD; Collantes Estévez E; Fernández Carballido C; Fernández Sueiro JL; García de Vicuña R; González-Álvaro I; González Fernández C; Juanola X; Linares LF; Marenco JL; Martín Mola E; Moreno Ramos M; Mulero Mendoza J; Muñoz Fernández S; Queiro R; Richi Alberti P; Sanz J; Tornero Molina J; Zarco Montejo P; Carmona L; Reumatol Clin; 2011; 7(5):284-98. PubMed ID: 21925444 [TBL] [Abstract][Full Text] [Related]
11. How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease. Richards JS; Dowell SM; Quinones ME; Kerr GS BMJ; 2015 Aug; 351():h3658. PubMed ID: 26282936 [TBL] [Abstract][Full Text] [Related]
12. New age of biological therapies in paediatric rheumatology. Sen ES; Ramanan AV Arch Dis Child; 2014 Jul; 99(7):679-85. PubMed ID: 24621445 [TBL] [Abstract][Full Text] [Related]
13. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Kavanaugh A Curr Opin Rheumatol; 2009 Jul; 21(4):419-24. PubMed ID: 19444117 [TBL] [Abstract][Full Text] [Related]
14. Vaccines and biologics. Ferreira I; Isenberg D Ann Rheum Dis; 2014 Aug; 73(8):1446-54. PubMed ID: 24845388 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ; Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075 [TBL] [Abstract][Full Text] [Related]
16. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Bello SL; Serafino L; Bonali C; Terlizzi N; Fanizza C; Anecchino C; Lapaldula G Reumatismo; 2012 Dec; 64(5):299-306. PubMed ID: 23256105 [TBL] [Abstract][Full Text] [Related]